[1] LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.
[2] WANG W, JIANG B, SUN H, et al. Prevalence, incidence and mortality of stroke in China clinical perspective[J]. Circulation,2017,135(8):759-771.
[3] 王晓勇, 骆守真, 崔春丽. 银杏二萜内酯葡胺注射液治疗急性脑梗死临床研究[J]. 河北中医, 2017,39(9):1328-1331.
[4] 李海龙, 尹晓新. 银杏二萜内酯葡胺注射液治疗急性缺血性脑卒中的临床观察[J]. 现代医院,2017,17(2):239-240.
[5] 骆继业, 谢永鹏, 陈晓兵,等. 银杏二萜内酯葡胺注射液治疗老年急性脑梗死疗效观察[J]. 世界最新医学信息文摘,2017,17(58):16-18.
[6] 王敏, 蔡胜男, 李迪,等. 银杏二萜内酯葡胺注射液对急性脑梗死患者神经功能的影响[J]. 中国实用神经疾病杂志,2016,19(7):29-31.
[7] 邱斌, 肖展翅. 银杏二萜内酯葡胺注射液治疗急性脑梗死的临床观察[J]. 中西医结合心脑血管病杂志,2015,13(8):1033-1035.
[8] 高聚, 姜华, 肖展翅,等. 银杏二萜内酯葡胺注射液治疗急性脑梗死的临床疗效观察[J]. 实用心脑肺血管病杂志, 2015,23(4):133-134.
[9] 肖展翅, 倪小红, 李钢,等. 银杏二萜内酯葡胺注射液对脑梗死恢复期患者血液流变学的影响[J]. 中西医结合心脑血管病杂志,2015,13(16):1828-1830.
[10] 赵宾江, 王振中, 凌娅,等. 银杏二萜内酯葡胺注射液治疗动脉粥样硬化性血栓性脑梗死恢复期(痰瘀阻络证)Ⅲ期临床试验[D]. 中草药,2013,44(24):3525-3530.
[11] 华玉凡. 银杏二萜内酯葡胺注射液治疗缺血性卒中恢复期(痰瘀阻络证)的临床研究[D]. 武汉:湖北中医药大学,2015.
[12] 张雯, 宋俊科, 何国荣,等. 银杏二萜内酯对缺血/再灌注大鼠脑组织中神经递质的影响[J]. 中国药理学通报,2016,32(12):1648-1656.
[13] WANG X, JIANG C M, WAN H Y, et al. Neuroprotection against permanent focal cerebral ischemia by ginkgolides A and B is associated with obstruction of the mitochondrial apoptotic pathway via inhibition of c-Jun N-terminal kinase in rats[J]. J Neurosci Res, 2014,92(2):232-242.
[14] GU J H, GE J B, LI M, et al. Inhibition of NF-kappaB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury[J]. Eur J Pharmac Sci,2012,47(4):652-660.
[15] MA S, YIN H, CHEN L, et al. Neuroprotective effect of ginkgolide K against acute ischemic stroke on middle cerebral ischemia occlusion in rats[J]. J Nat Med,2012,66(1):25-31.